SIRT6 variants from centenarians reduce cellular senescence burden and reveal senotherapy targets

An international research team has identified SIRT6 gene variants enriched in Ashkenazi Jewish centenarians that significantly reduce senescent cell burden in aged tissues. Researchers introduced these two linked variants into human embryonic stem cells and demonstrated they elevated endogenous SIRT6 protein abundance through weakened vimentin interaction while simultaneously altering enzymatic activities: enhancing mono-ADP-ribosyltransferase activity and reducing deacetylase function. Functionally, these variants delayed replicative senescence and conferred resistance to progerin-induced stress while preserving DNA repair gene expression and suppressing transposable element derepression. Beyond the descriptive value of these genetic findings, the authors evaluated pharmacological interventions—including adeno-associated virus delivery of centenarian SIRT6 and SIRT6 activation via fucoidan from *Fucus vesiculosus*—demonstrating partial attenuation of aging-associated molecular defects in progeria fibroblasts. For the longevity-conscious reader, the practical implication is unambiguous: emphasis should shift from emulating specific genetic variants toward developing superior senolytic compounds capable of selectively removing senescent cells from the body on an ongoing basis, a more potent strategy than genetic replication alone.